Unpredictability of Counterfeit Drugs

Novel Psychoactive Substances (NPS) are developed to bypass controlled drug legislation and evade detection by traditional drug testing methods. In many…

Novel Psychoactive Testing in Oral Fluid

Novel Psychoactive Substances Added to Oral Fluid Testing Menu Aegis’ oral fluid testing menu has been expanded to allow providers the option to test…

Opioid Drug Interactions: Ongoing Awareness Amidst the COVID-19 Pandemic and Opioid Epidemic

In recent years, there has been a significant growth in the understanding of prescription opioid use and misuse, addiction, and overdose.  This has led…

Staying Safe: The Importance of Medication Monitoring as the Pandemic Continues

The COVID-19 pandemic continues to pose significant challenges to the healthcare system, despite widespread availability of vaccines. Variants of the virus…

Cases of Unusual Buprenorphine Concentrations in Urine Drug Tests: What Does This Mean and Clinical Implications?

Buprenorphine is a semisynthetic opioid with partial agonist activity at the mu-opioid receptor, an effective treatment option for opioid use disorder…

NPS Focus: “Nitazene" Synthetic Opioids

Aegis launched an extensive and industry-leading testing menu of Novel Psychoactive Substances (NPS) in mid-2020, which includes phenibut, tianeptine,…

Finding Fentanyl

Synthetic opioids, including fentanyl, buprenorphine, meperidine, methadone and others,1 comprise a class of drugs manufactured in laboratories designed…